MorphoSys acquires Sloning BioTechnology
This article was originally published in Scrip
Executive Summary
MorphoSys, the antibody technology company, is using some of its cash pile (approximately €150 milion as of June 2010) to improve the R&D productivity of its platform. MorphoSys is acquiring another Munich-based firm, Sloning BioTechnology, for €19 million cash to access its Slonomics technology which it says offers precise and rapid synthesis of protein libraries which should enable it to cut the time needed to generate an antibody drug candidate by a third.